Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2018-03-29 / Cancer Immunol Immunother 2018 Dec;67(12):1897-1910Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-26 / Oncoimmunology 2018;7(7):e1445457Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations
/in Dendritic Cells, Hepatocellular Carcinoma, International Publications /von 2018-03-26 / J Immunol Res 2018;2018:8740976Dendritic cells as cancer therapeutics
/in Dendritic Cells, International Publications /von 2018-03-21 / Semin. Cell Dev. Biol. 2019 Feb;86:77-88Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-18 / J Immunol Res 2018;2018:3982942Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2018-03-01 / Front Immunol 2018;9:394Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2018-02-21 / Hum Vaccin Immunother 2018 Jun;14(6):1423-1431Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
/in Acute Leukemia, Checkpoint-Inhibitors, Chronic Leukemia, Dendritic Cells, International Publications /von 2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de